Isolated phages and their use in food or pet food products
AssigneeNestec S.A.
InventorsHarald Bruessow, Sandra Chennoufi, Josette Sidoti, Anne Bruttin
Life of this patent
Estimating the term…
Abstract
The present invention relates to phage isolates having a strong lytic activity against pathogenic Enterobacteriaceae such as Escherichia coli and/or Salmonella strains and their use in various human or pet food products for the treatment or prevention of bacterial diseases caused by pathogenic Enterobacteriaceae such as Escherichia coli, in particular for phage therapy of pediatric gastroenteritis, or Salmonella infection. It also relates to human or pet food products prepared thereof.
Claims6
1-18. (canceled)
A method of preventing or treating an infection caused by pathogenic Enteriobacteriaceae in humans or animals, the method comprising administering to an individual an effective amount of a phage preparation to prevent or treat the infection in the human or animal, the phage preparation comprising a broad host range isolated phage selected from the Myoviridae family having a genome size of 170 kb and lytic activity against pathogenic E. coli or Salmonella strains, wherein the isolated phage is virulent and safe to administer to a human or animal and wherein the isolated phage is an obligate virulent phage with a contractile tail.
The method of claim 30, wherein the pathogenic Enteriobacteriaceae is E. coli or Salmonella.
The method of claim 30, wherein the infection is gastroenteritis, diarrheal or urinary.
The method of claim 30, wherein the infection is traveler's diarrhea, Enterotoxigenic Escherichia coli (ETEC), or pediatric gastroenteritis.
The method of claim 30, wherein the amount is at least 1.104 pfu (plaque forming unit)/ml.
Dependencies are inferred from the claim text.